Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxaliplatin
Drug ID BADD_D01633
Description Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.
Indications and Usage Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.
Marketing Status approved; investigational
ATC Code L01XA03
DrugBank ID DB00526
KEGG ID D01790
MeSH ID D000077150
PubChem ID 9887053
TTD Drug ID D0Y3ME
NDC Product Code 0703-3986; 13808-502; 0955-1733; 25021-233; 68083-171; 72603-101; 0955-1727; 57884-0017; 63592-0700; 50742-406; 55150-332; 67184-0501; 68083-170; 68083-176; 0955-1731; 72659-865; 43066-014; 68001-468; 71288-101; 82920-704; 16729-332; 45963-611; 67184-0502; 67184-0509; 0781-3317; 0781-9317; 67457-469; 0703-3985; 54875-0006; 67184-0510; 67457-442; 68083-314; 72266-126; 0781-3315; 50742-405; 71288-149; 72266-162; 0781-9315; 55150-331; 61703-363; 63323-750; 67184-0508; 72266-125; 72266-161; 72603-301; 79672-825; 0955-1725; 53104-7649; 67184-0007; 68554-0083; 60505-6132; 68083-177; 79672-826; 14778-0404; 49812-0075; 43066-018
UNII 04ZR38536J
Synonyms Oxaliplatin | Oxalato-(1,2-cyclohexanediamine)platinum II | Oxaliplatin, (SP-4-2-(1R-trans))-isomer | L-OHP Cpd | Platinum(II)-1,2-cyclohexanediamine Oxalate | 1,2-Diaminocyclohexane Platinum Oxalate | 1,2 Diaminocyclohexane Platinum Oxalate | 1,2-Diamminocyclohexane(trans-1)oxolatoplatinum(II) | Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1) | Oxaliplatine | Eloxatine | Eloxatin | Oxaliplatin, (SP-4-3-(cis))-isomer | ACT 078 | ACT-078 | ACT078 | Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II) | Oxaliplatin, (SP-4-2-(1S-trans))-isomer
Chemical Information
Molecular Formula C8H14N2O4Pt
CAS Registry Number 61825-94-3
SMILES C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Menopausal symptoms21.02.02.002--Not Available
Metabolic acidosis14.01.01.003--Not Available
Metastases to liver16.22.02.001; 09.04.02.0040.001399%Not Available
Metastases to lung22.08.01.005; 16.22.02.0020.000672%Not Available
Microangiopathic haemolytic anaemia24.03.02.019; 01.06.02.0020.000112%Not Available
Miosis17.02.11.002; 06.05.03.0030.000168%Not Available
Monoparesis17.01.04.0110.000168%Not Available
Monoplegia17.01.04.0030.000280%Not Available
Mouth ulceration07.05.06.004--Not Available
Movement disorder17.01.02.010--Not Available
Mucosal inflammation08.01.06.0020.001287%Not Available
Mucosal ulceration08.01.06.003--Not Available
Muscle contractions involuntary17.05.03.001; 15.05.03.0080.000560%Not Available
Muscle rigidity17.05.02.005; 15.05.04.0010.001399%Not Available
Muscle spasms15.05.03.0040.005440%
Muscle twitching15.05.03.0050.000884%Not Available
Muscular weakness15.05.06.001; 17.05.03.0050.001959%
Myalgia15.05.02.001--
Myelodysplastic syndrome16.01.04.001; 01.10.04.0010.000280%
Myocardial ischaemia02.02.02.008; 24.04.04.0100.000672%Not Available
Myocarditis02.04.03.0010.000168%
Myoclonus17.02.05.008--Not Available
Nail disorder23.02.05.002--
Nasal obstruction22.12.03.0130.000224%Not Available
Nasopharyngitis11.01.13.002; 22.07.03.002--Not Available
Nausea07.01.07.0010.019800%
Necrosis24.04.02.006; 08.03.03.0010.000112%Not Available
Neoplasm malignant16.16.01.001--Not Available
Nephropathy20.05.03.0010.000112%Not Available
Nephropathy toxic12.03.01.010; 20.05.03.0020.000728%Not Available
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 24 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene